The neonatal gut microbiome and global health

ABSTRACT

The role of gut microbiome in health, a century-old concept, has been on the center stage of medical research recently. While different body sites, disease conditions, and populations have been targeted, neonatal and early infancy appear to be the most suitable period for such interventions. It is intriguing to note that, unlike traditional use in diarrhea and maintenance of gastrointestinal health, microbiome-mediating therapies have now addressed the most serious medical conditions in young infants such as necrotizing enterocolitis and neonatal sepsis. Unfortunately, almost all new endeavors in this space have been carried out in the Western world leaving behind millions of neonates that can benefit from such manipulations while serving as a large resource for further learning. In this review, an attempt has been made to quantify the global burden of neonatal morbidity and mortality, examples presented on interventions that have failed as a result of drawing from studies conducted in the West, and a case made for manipulating the neonatal gut microbiome to address the biggest killers in early life. A brief comparative analysis has been made to demonstrate the differences in the gut microbiota of North and South and a large clinical trial of synbiotics conducted by our group in a South Asian setting has been presented. Although challenging, the value of conducting such global health research is introduced with an intent to invite medical scientists to engage in well-planned, scientifically robust research endeavors. This can bring about innovation while saving and serving the most vulnerable citizens now and protecting them from the negative health consequences in the later part of their lives, ultimately shaping a resilient and equitable world as pledged by 193 United Nations member countries in 2015.

KEYWORDS:

• Gut microbiota
• neonatal sepsis
• stunting
• gut dysfunction
• gut permeability
• antimicrobial resistance
• lactobacillus
• prebiotics
• synbiotics
• probiotics

Disclosure statement

Pinaki Panigrahi developed the Lactiplantibacillus plantarum strain ATCC-202195 which has been licensed (as PPLP-217TM) to Chr Hansen for commercial production and sale as food/supplement following Georgetown University institutional policies.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.